Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT07017686

The Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis

Led by The Bionics Institute of Australia · Updated on 2025-09-22

5

Participants Needed

3

Research Sites

326 weeks

Total Duration

On this page

Sponsors

T

The Bionics Institute of Australia

Lead Sponsor

S

St Vincent's Hospital Melbourne

Collaborating Sponsor

AI-Summary

What this Trial Is About

This open label clinical trial aims to assess the safety of abdominal vagus nerve stimulation (aVNS) for moderate to severe, adult-onset rheumatoid arthritis (RA) that has not responded to medication. The aVNS is an active medical device placed into the body to allow electrical stimulation of the abdominal vagus nerve. Participants will undergo stimulation treatment with the aVNS device from two to 24 weeks after the device is implanted by keyhole surgery. Safety, device performance and potential benefits will be assessed. Participants will be monitored for specific events for 5 years post surgery.

CONDITIONS

Official Title

The Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 to 75 years
  • Adult-onset rheumatoid arthritis (onset at age 18 or above) confirmed by 2010 ACR/EULAR criteria and positive Rheumatoid Factor or specific antibody tests
  • Moderate to severe active RA with at least 4 tender and 4 swollen joints out of 28
  • Active disease not responding to a 3-month trial or intolerant to at least 2 biologic or targeted synthetic DMARDs
  • Stable dose of at least one biological or synthetic DMARD for more than 8 weeks before screening and during the trial
  • Women of childbearing potential must not be pregnant or trying to become pregnant and agree to use effective contraception
  • Eligibility for Medicare
  • Ability to provide informed consent by signing a consent form
Not Eligible

You will not qualify if you...

  • Unable or unwilling to provide written informed consent
  • Current major psychiatric disorder except stable, well-controlled major depression or anxiety
  • Medical conditions interfering with study procedures or endpoint evaluation
  • Severe autonomic neuropathy such as poorly controlled type 2 diabetes or metabolic disease
  • History of previous surgeries including vagotomy, splenectomy, or bariatric surgery
  • History of gastric hiatus hernia
  • Previously implanted active medical devices or likely need for such devices within 6 months
  • Conditions requiring routine MRI scans
  • Considered unsuitable for the trial by the Principal Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Bionics Institute

Fitzroy, Victoria, Australia, 3065

Actively Recruiting

2

St Vincent's Hospital, Department of Rheumatology

Fitzroy, Victoria, Australia, 3065

Actively Recruiting

3

Austin Health, Heidelberg Repatriation Hospital

Ivanhoe, Victoria, Australia, 3079

Actively Recruiting

Loading map...

Research Team

A

A/Prof Shereen Oon, MBBS, PhD

CONTACT

A

Angela Chia, RN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DEVICE_FEASIBILITY

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here